Slide 1: Gilead to Acquire Tubulis, Ouro and Arcellx
Gilead to Acquire Tubulis, Ouro and Arcellx 7 April 2026
Slide 2: Forward-Looking Statements
® Forward-Looking Statements This presentation contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as “ambition,”
Slide 3: Gilead’s Planned Acquisitions Further Strategic Goals
Gilead’s Planned Acquisitions Further Strategic Goals • TUB-040 Shows Compelling, Transformative Potential in Ovarian Cancer Adding Potential Best-in- • Tubulis Expands R&D Capabilities with Next-Generation ADC Platform 1 Disease & First-in-Class • Ouro Adds B Cell Depleting TCE with Potential for “
Slide 4: Tubulis: Potential to Transform Ovarian Cancer
Tubulis: Potential to Transform Ovarian Cancer Strategic Opportunity Next-Gen Platform Potential Best-in-Disease ADC: P5 Conjugation: Highly stable linker $3.15B Compelling TUB-040 Ph1 data in ovarian cancer; in Ph2 portion of study technology producing high DAR ADCs Upfront Payment Alco5: Unlock pr
Slide 5: TUB-040: High Impact Opportunity in Ovarian Cancer
TUB-040: High Impact Opportunity in Ovarian Cancer NaPi2b is highly expressed in ovarian cancer cells 90% Tumor Expression (%) TUB-040 80% 70% NaPi2b ADC 60% NaPi2b FRα CDH6 Ovarian Cancer Opportunity Sources: Zannoni GF, et al. Int J Mol. Sci 2025. Shintani D, et al. SGO 2022. • Large Unmet Need: >
Slide 6: Ouro: Foundation for “Immune Reset” Therapies
Ouro: Foundation for “Immune Reset” Therapies Strategic Opportunity OM336 (gamgertamig) BCMAxCD3 TCE $1.675B Orphan Diseases: Accelerates Gilead’s entry into I&I market Potential Best-in-Class Opportunity: Superior potency, SC administration, Upfront Payment Split with Galapagos lower CRS Galapagos
Slide 7: Arcellx: Unlocking Blockbuster Potential of Anito-Cel
Arcellx: Unlocking Blockbuster Potential of Anito-Cel Strategic Opportunity Anito-cel BCMA CAR T $7.8B Strategic Fit: Significantly expands Best-in-Disease Potential: Deep, Implied Equity Value1 commercial potential for Kite, leveraging durable efficacy; no delayed our end-to-end expertise neurotox;
Slide 8: P&L Impact of Transactions
P&L Impact of Transactions Transaction related in process R&D expense will be shared as each transaction closes FY26 guidance will be updated in due course; excluding deal IPR&D, do not expect significant increases in 2026 OpEx Expect modest & manageable R&D increase vs initial guidance; FY26 R&D ex
Slide 9: Commitment to Disciplined Capital Deployment
Commitment to Disciplined Capital Deployment Priorities for 2026 Capital Allocation Priorities Largely Unchanged Focus on Successful Integration Invest in our business to support commercial launches and R&D of Arcellx, Ouro and Tubulis pipeline while managing expenses Ordinary Course Licensing and P
Slide 10: Q&A
Daniel O’Day Dietmar Berger, MD, PhD Cindy Perettie Q&A Chairman & Chief Medical Officer EVP & Head of Kite Chief Executive Officer Andrew Dickinson Johanna Mercier Chief Financial Officer Chief Commercial and Corporate Affairs Officer